Abdi İbrahim Extends its Healing Touch to the Gulf

Abdi İbrahim forms a joint venture with Saudi Cigalah Healthcare, laying the foundation for expansion into Saudi Arabia and beyond, prioritizing exports as the initial step.

Abdi İbrahim extends its healing touch to the Gulf

Maintaining its uninterrupted leadership in the Turkish pharmaceutical industry for 22 years, Abdi İbrahim has made yet another addition to its strong roster of business allies, setting its sights on the Gulf markets. Through the partnership with Cigalah Healthcare, a leading pharmaceutical and consumer health company in Saudi Arabia and the Gulf region, Abdi İbrahim's innovative medicines will be exported to countries in the region, starting with Saudi Arabia. Describing the partnership, which proposes technology transfer for the production of some products in Saudi Arabia within two years and local production afterward, as a "historic milestone", Abdi İbrahim Chairman Nezih Barut said, " This joint venture fills us with pride as we bring innovative medicines to the Saudi people and bolster our nation's economy through exports. Anticipating the beginning of a success story, our journey starts in the Saudi market, with plans to expand throughout the Gulf region. We aspire for this narrative to serve as a pivotal model for economic cooperation between Türkiye and Saudi Arabia. Teaming up with two illustrious companies with centuries-old legacies, we are committed to achieving success through diligent effort.”

Abdi İbrahim, the healing power of Türkiye, has forged yet another significant partnership in alignment with its global expansion strategy. "Abdi Cigalah Pharma," a joint venture entity established with a 50 percent stake held by Cigalah Healthcare, a prominent entity in Saudi Arabia and the Gulf region's pharmaceutical and consumer health sectors, was unveiled during a signing ceremony in Jeddah, Saudi Arabia on April 29.Abdi İbrahim Chairman Nezih Barut, Abdi İbrahim CEO Dr. Süha Taşpolatoğlu, and Cigalah Healthcare Chairman Yaser Naghi attended the partnership signing ceremony. This alliance is poised to facilitate Abdi İbrahim's robust entry into the Gulf region, identified as a strategic priority.

The alliance between Abdi İbrahim, Türkiye's venerable pharmaceutical leader boasting a 112-year legacy, and Cigalah Healthcare, Saudi Arabia's century-old stalwart, encompasses the export of Abdi İbrahim's cutting-edge products to Gulf nations, starting with the Saudi market. As part of the collaboration, there are also intentions to conduct secondary packaging for select products from Türkiye within Saudi Arabia, along with initiating technology transfer processes for local production of certain products within the Saudi borders over the coming two years.

"Although we're a 100% local enterprise, our aspirations span the globe"

Speaking at the ceremony, Nezih Barut commenced his speech by extending gratitude to Cigalah Healthcare Chairman and CEO Yaser Naghi, whom he fondly referred to as "my friend and partner," along with the entire team at Cigalah Healthcare, for their hospitality. Characterizing the partnership announcement as a momentous milestone, Nezih Barut, chairman of Türkiye's longest standing and largest pharmaceutical company, expressed that Cigalah Healthcare’s accomplishments across various sectors in the Saudi market served as a catalyst for collaboration. He remarked: "For 112 years, we have remained a purely local Turkish pharmaceutical enterprise. Yet our vision has always reached beyond borders. Our ambition is to ascend to the ranks of the world's top 100 pharmaceutical firms, embodying sustainability, innovation, and purpose. Hence, we have forged invaluable partnerships and joint ventures with leading international pharmaceutical entities. Today, we proudly introduce Abdi Cigalah Pharma—a partnership with Cigalah Healthcare—which stands shoulder to shoulder with these strong alliances. This is a proud moment for all.”

Products first, then technology transfer

Barut affirmed their commitment to offering Abdi İbrahim's cutting-edge products to the people of Saudi Arabia through the newly established company, in which Abdi İbrahim holds a 50 percent stake, with the remaining 50 percent owned by Cigalah Healthcare. He disclosed collaborations with Alpha Pharma, a subsidiary of Cigalah Healthcare, in production, and with the organization itself in marketing. "On one front, we will export Abdi İbrahim's pharmaceuticals from Türkiye. Simultaneously, we will bolster local pharmaceutical production in Saudi Arabia by conducting secondary packaging for select products originating from Türkiye. Furthermore, we are already strategizing our investments to facilitate technology transfers for local production in Saudi Arabia within the next two years," Barut emphasized, underscoring the meticulous planning behind the portfolio of Abdi Cigalah Pharma, headquartered in Jeddah.

"Our ambition is to surpass over $133 million in size within five years”